Aeterna Zentaris Mails Management Information Circular in Connection with Annual Meeting of Shareholders
03 April 2017 - 10:00PM
Business Wire
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna
Zentaris” or the “Company”) today announced that it has mailed a
Notice of Meeting and Management Information Circular (the “Meeting
Materials”) to the shareholders of record as of March 20, 2017 in
connection with its Annual Meeting of shareholders (the “Meeting”)
to be held at the offices of Norton Rose Fulbright Canada, 1 Place
Ville-Marie, Suite 2500, in Montreal, Canada on Tuesday, May 9,
2017 at 10:00 a.m. (Eastern Time). The Meeting Materials can be
found at www.aezsinc.com or on the Company’s SEDAR profile at
www.sedar.com.
HOW TO VOTE
The cut-off time for voting is 5:00 p.m. (Eastern Time) on May
5, 2017.
Registered shareholders (those who hold Aeterna Zentaris shares
in their name and represented by a physical certificate) may vote
by mail, internet, telephone or in person at the Meeting. In the
interest of time, shareholders are encouraged to vote via the
internet or by telephone using the control number located on their
proxy as follows:
- Internet: Go to the website
www.investorvote.com and follow the instructions on the
screen.
- Telephone: Voting by proxy using the
telephone is only available to shareholders located in Canada and
the United States. Call 1-866-732-VOTE (8683) toll-free in Canada
and 1-312-588-4290 toll-free in the United States from a touchtone
telephone and follow the instructions provided.
Beneficial shareholders (those who hold Aeterna Zentaris shares
through a bank, broker or other intermediary) will have different
voting instructions provided to them and should follow the
instructions found on their voting instruction form.
The Board of Aeterna Zentaris UNANIMOUSLY recommends that
shareholders vote IN FAVOUR of all the proposed resolutions.
Your vote is important regardless of how many shares you own.
The Company encourages shareholders to read the Meeting Materials
in detail.
Shareholders who have questions or have not received their proxy
or voting instruction form may contact Aeterna Zentaris’ Proxy
Solicitation Agent:
Laurel Hill Advisory Group
Toll free: 1-877-452-7184 or 416-304-0211
Email: assistance@laurelhill.com
About Aeterna Zentaris
Aeterna Zentaris is a specialty biopharmaceutical company
engaged in developing and commercializing novel treatments in
oncology, endocrinology and women’s health. We are engaged in drug
development activities and in the promotion of products for others.
We recently completed Phase 3 studies of two internally developed
compounds. The focus of our business development efforts is the
acquisition of licenses to products that are relevant to our
therapeutic areas of focus. We also intend to license out certain
commercial rights of internally developed products to licensees in
non-U.S. territories where such out-licensing would enable us to
ensure development, registration and launch of our product
candidates. Our goal is to become a growth-oriented specialty
biopharmaceutical company by pursuing successful development and
commercialization of our product portfolio, achieving successful
commercial presence and growth, while consistently delivering value
to our shareholders, employees and the medical providers and
patients who will benefit from our products. For more information,
visit www.aezsinc.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170403005024/en/
Aeterna Zentaris Inc.Philip A. Theodore, 843-900-3223Senior Vice
Presidentir@aezsinc.com
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Apr 2024 to May 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From May 2023 to May 2024